Metropolis Healthcare study reveals average 8.73 percent cancer positivity

Mumbai : Metropolis Healthcare Ltd, a leading player in pathology services that specializes in cancer testing released data points that showed that 8.73% of the over 1.5 Lakh tissue sample cases tested across multiple cities in India were positive for different types of cancer. The research is based on tissue samples submitted by patients across age groups conducted from year 2013 to 2015.

Of the various cancers detected, cancers of breast, oral cavity, gastrointestinal and hepato-billiary tract and cervix emerged as a dominant and more commonly occurring in recent times. These are followed by cancers of prostate, urinary bladder, hemato-lymphoid and lung which show increase in the trend over the period of three years.

The samples tested and observed were from Ahmedabad, Chennai, Delhi, Pune, Guwahati, Indore, Mumbai and Bangalore. A closer study of the 3-year data revealed that urban cities have demonstrated an upward trend in the number of overall cancer positivity.

Dr Sushil Shah, Chairman, Metropolis Healthcare Ltd. said, ‘’India is faced with a crisis in terms of the number of onco-specialists that are available in the country. To ease the burden of Diagnosis, we are very happy to have launched Oncomet which provides diagnostic, predictive and prognostic support. We are impacting thousands of lives each year through our Oncomet Initiative.”

Dr Kirti Chadha, Head of Oncology, Metropolis Healthcare said, “Some of the most common cancers affecting women in India are cancers of the breast and cervix. Men in India on the other hand mainly suffer from oral cancer, gastrointestinal tract, lung and prostate. One of the major reasons for the rise in these particular cancers is increase in tobacco and alcohol consumption, and a sedentary lifestyle. We have noticed a gradual increase in cancer diagnosis cases during these three years, which is 7.32% in 2013 to 10.1% in 2015. The important truth about cancer is that most of the cancers can be prevented or detected at an early stage and cured more effectively. At Metropolis, our goal with each sample is to offer conclusive diagnosis at an affordable cost.”